

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) Publication number:

**0 327 429 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**(45) Date of publication of patent specification: **22.09.93** (51) Int. Cl.<sup>5</sup>: **C12Q 1/68, C12N 15/10**(21) Application number: **89400220.3**(22) Date of filing: **26.01.89**(54) **Labeling by simultaneous ligation and restriction.**(30) Priority: **26.01.88 US 148757**(43) Date of publication of application:  
**09.08.89 Bulletin 89/32**(45) Publication of the grant of the patent:  
**22.09.93 Bulletin 93/38**(84) Designated Contracting States:  
**CH DE FR GB IT LI SE**

(56) References cited:

**EP-A- 0 130 515****EP-A- 0 185 494****EP-A- 0 246 864**

**NUCLEIC ACIDS RESEARCH**, vol. 13, no. 1,  
1985, pages 45-57, IRL Press Ltd, Oxford, GB;  
**T. KEMPE et al.**: "Chemical and enzymatic  
biotin-labelling of oligodeox-  
ynucleotides"

**SCIENCE**, vol. 230, December 1985, pages  
1350-1354, Washington D.C., US; **R.K. SAIKI et  
al.**: "Enzymatic amplification of beta-globin  
genomic sequences and restriction site ana-  
lysis for diagnosis of sickle cell anemia"

(73) Proprietor: **APPLIED BIOSYSTEMS, INC.**  
**850 Lincoln Centre Drive**  
**Foster City California 94404(US)**

(72) Inventor: **Keith, Douglas H.**  
**1145 Glencourt Drive**  
**Oakland, CA 94611(US)**  
Inventor: **Kronick, Mel N.**  
**1156 Forest Avenue**  
**Palo Alto, CA 94301(US)**  
Inventor: **McBride, Lincoln J.**  
**311 Iris Street**  
**Redwood City, CA 94062(US)**  
Inventor: **Whiteley, Norman M.**  
**151 Highland Avenue**  
**San Carlos, CA 94070(US)**

(74) Representative: **Warcoin, Jacques et al**  
**Cabinet Régimbeau 26, avenue Kléber**  
**F-75116 Paris (FR)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

NUCLEIC ACIDS RESEARCH, vol. 14, no. 22, 1986, pag 9219, IRL Press Ltd, Oxford, GB; P.K. ROGAN: "Restriction mapping by preferential ligation of adjacent digestion fragments"

CHEMICAL ABSTRACTS, vol. 89, 1978, page 223, no. 55479f, Columbus, Ohio, US; V. SGARAMELLA et al.: "Use of the T4 polynucleotide ligase in the joining of flush-ended DNA segments generated by restriction endonucleases", & EUR. J. BIOCHEM. 1978, 86(2), 531-7

Nucleic Acids Research, Vol.12, No. 4, 1984, Oxford. M.C.Hung and P.C. Wensink. "Different restriction enzyme-generated sticky DNA ends can be joined in vitro", pages 1863-1874

---

## Description

### INTRODUCTION

#### 5 Technical Field

Method for labeling nucleic acid fragments for detection.

#### Background

10 Today, biology is in many ways the science of proteins and nucleic acids. Nucleic acids are found in all living matter. For each species or host, unique sequences exist providing for the genotype and phenotype of that particular host. Thus, one can use the presence of a particular sequence as indicative of the particular strain or species. In many instances, a number of strains will share a common sequence as  
 15 distinct from other strains or species, so that one can not only detect a particular strain but, if desired, can detect subspecies, species or genera. In addition, one can distinguish between RNA or DNA so as to determine whether a particular gene is being expressed, the existence of one or more alleles, the level of expression, and the like. Where cells, such as B-cells and T-cells, are involved with genomic rearrangements, one can detect the presence or absence of such rearrangements by employing probes. Thus, the  
 20 detection of particular nucleic acid sequences is a powerful tool in the diagnosis of disease states, the presence of sets or subsets of cells, the particular strain or species of a pathogen, such as a bacterium, protista, or virus, or the like.

The detection and isolation of sequences is also important in the field of molecular biology. Thus, the use of probes allows for detection of a variety of sequences of interest, including structural genes,  
 25 regulatory sequences, introns, exons, leader sequences, both translated and untranslated, and the like.

There is also substantial interest in detecting sequences in genetic engineering. Monitoring levels of transcription, detecting the integrity of constructs, monitoring levels of mutation, resection, mapping, or the like provide opportunities for nucleic acid screening and detection.

In many instances, the sequence of interest may be present as only a very small fraction of the total  
 30 amount of nucleic acid, and/or in very small amount, e.g. attomole levels. Furthermore, the sequence of interest may be accompanied by a number of sequences having substantial homology to the sequence of interest. Thus, relatively high stringencies may be required to ensure the absence of unwanted heteroduplexing, which may further limit the available concentration of the sequence of interest.

Additionally, the same or similar sequences may appear on nucleic acid fragments of different size and  
 35 the appearance of a sequence on a particular size fragment may be correlated to the presence of a particular phenotype.

There is also interest in developing analytical systems which can be automated, so as to minimize the time and energy required from technicians, as well as minimizing errors which may result from manual manipulation. In many systems the sample is labeled to allow for detection of the sequence. The labeling  
 40 can be time consuming and limited as to the nature of the label as in nick translation with radioactive nucleotide triphosphates. In other situations, the particular nature of the label may be limited, as when using terminal deoxytransferase. Other techniques result in random substitution. There is therefore an interest in providing for rapid convenient controlled labeling of sample nucleic acids, where the labeled moiety may be commercially available and require little, if any, technical skills in being used to label the sample.

#### 45 Relevant Literature

Kempe et al., Nucl. Acids. Res. (1985) 13:45-57 describe biotinylated oligonucleotides linked to DNA fragments by a ligase. Gamper et al., Nucl. Acids Res. (1985) 14:9943-9954, employs a psoralen-functionalized oligomer as a probe which labels target DNA when hybridization and photochemical cross-linking occur. Zapolski et al., Electrophoresis (1987) 8:255-261 discuss a robotic system for automating Southern-type nucleic acid hybridization analysis. Goldkorn and Prockop, Nucl. Acids Res. (1986) 14:9171-9191 describe techniques for covalent attachment of DNA probes to cellulosic supports for hybridization-restriction analysis. Syvanen et al., Nucl. Acids Res. (1986) 14:5037-5048 quantify nucleic acid hybrids by  
 50 affinity-based hybrid collection. Forster et al., Nucl. Acids Res. (1985) 13:745-761 covalently label nucleic acids with biotin photochemically. Hung and Wensink, Nucl. Acids Res. (1984) 12 : 1863-1874 discloses adapters which can be ligated to sticky ends and wherein the formed fragment is insensitive to the restriction enzyme creating the sticky end.

## SUMMARY OF THE INVENTION

Double-stranded DNA ("dsDNA") fragments are labeled with detectable double-stranded nucleic acid that possesses a terminus complementary to at least one terminus of the double-stranded DNA fragments to be labeled. The labeling double-stranded sequence contains either a label or sequence that can subsequently be detected or isolated. The labeling reaction is performed using ligase to couple the complementary ends and a restriction enzyme to produce the complementary ends on the DNA fragment and to prevent unintended ligation of the fragments to each other. Joining of the nucleic acid labeling segment to the dsDNA fragment results in loss of the restriction enzyme recognition sequence.

## DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods and compositions are provided for labeling a ds nucleic acid fragment in a sample. The method involves ligating the label onto the fragment in the simultaneous presence of a restriction enzyme, where ligation results in loss of the restriction enzyme recognition sequence.

The subject method finds use in a number of situations. One application is in the detection of DNA samples, wherein the probe so labeled serves to link the labeled sample sequence to a solid support. Another situation is in the addition of a particular sequence to restricted sequences, preventing oligomerization of the restricted sequences, while using substantially stoichiometric amounts of the moiety containing the desired sequence. The sequence may be a template or a promoter sequence, a specific sequence for detection or use, for example in the polymerase chain reaction as used in DNA amplification schemes, or the like. Another use is to change the nature of the terminus while removing a restriction site. The labeling procedure would also be useful for labeling DNA restriction fragments which will be sized and detected in order to map regions of DNA.

Usually, the sample employed will be genomic or cDNA involving a plurality of different restricted fragments, generally at least two different fragments, more usually five or more fragments, and may be 50 or more or even thousands or millions of fragments.

The method described above for labeling double-stranded DNA with a ligand using ligation in combination with restriction enzymes is very general and can be used in any procedure where it is desired to covalently attach a ligand to dsDNA. By ligand is intended any moiety of interest, which may be a label allowing for detection, a nucleic acid sequence providing a desired function, a coupling molecule, etc. It is described herein how such a labeling procedure is applied to assays for detection of specific nucleic acid sequences using probes for such sequences. The use of different detectable labels with different colors or fluorescent emission wavelengths would enable the mapping to occur with greater efficiency by using one color attached to a size standard and another one (or more) as samples cut by the same or different restriction enzymes. Hence the ligation/restriction labeling procedure is useful for the production of labeled fragments for any subsequent length analysis.

Alternatively, the same ligation/restriction labeling procedure could be used to add a given oligonucleotide sequence or sequences to the ends of a DNA fragment instead of adding a moiety to be detected. Such an oligonucleotide sequence would prove very valuable, for example, as a primer sequence for DNA or RNA polymerase that would be used to transcribe or reproduce the DNA fragment of interest. In such a fashion, the DNA fragment could be ligated to primers and then amplified by means of a polymerase chain reaction. (Saiki et al., *Science* (1985) 230:1350 ff.) These added defined sequence regions could also be used as a target sequence for a probe used to identify or to pull out the fragment of interest. In this and all other examples of the ligation/restriction procedure the ligated double-stranded pieces added may be synthesized organically, enzymatically, biologically or in some combination of methods.

The use of the subject method will be primarily illustrated in a diagnostic system, where a DNA sample is fragmented using endonuclease cleavage (restriction), followed by labeling.

The source of the sample may be any material or substance comprising nucleic acid. The nucleic acid need not be a naturally occurring nucleic acid, but may be synthesized chemically, enzymatically, or biologically and may have other than naturally occurring purines and pyrimidines. The sample source may be cellular or non-cellular, may be a clinical sample or isolate, may be derived from such physiological media as blood, serum, plasma, stool, pus, scrapings, washings, urine, or the like; may be associated with a set or subset of cells, such as neoplastic cells, lymphocytes, e.g. T-cells or B-cells, monocytes, neutrophils, etc. pathogens, including viruses, bacteria, mycoplasma, fungi, protozoa, etc. may include constructs, involving plasmids, viruses or DNA or RNA fragments, or the like. The nucleic acid sample may involve DNA, which may be chromosomal or extrachromosomal, e.g. plasmids, viruses, synthetic constructs, etc. or RNA, such as messenger RNA, transfer RNA, ribosomal RNA, viruses, or the like, where the RNA may be

transcribed into dsDNA. The nucleic acid sequences may involve structural genes, untranslated regions, regulatory regions, introns, exons, or the like.

The detection may be for a wide variety of purposes. Detection may involve diagnosis of a diseased state in plant or animal species, such as neoplasia or other aberrant cellular state, the detection of sets or subsets of cells, such as lymphocytes at various stages of differentiation, the detection of strains or species of pathogens, the monitoring of genetic engineering, or the like. Prior to use of the sample in the subject invention, the sample may have been subjected to a variety of chemical or physical treatments, such as proteolysis, extraction, precipitation, separation of nucleic acid from other components, such as lipids, proteins, or the like, hydrolysis of RNA, inactivation of nucleases, concentration, chromatography, dehydration, heating, etc. The sample may be manipulated for a variety of reasons, such as removal of interfering materials, preparation for storage or shipment, concentration, or the like.

The composition will normally be subjected to fragmentation by employing restriction enzymes. The restriction enzymes will cleave in the recognition site, usually having a 4 to 8bp recognition site. One or more restriction enzymes may be employed where, depending upon the nature of the sample, fragments may be provided varying from 50bp to 200kbp or more, more usually from about 0.5 to 25kbp. Various restriction enzymes may be used resulting in the formation of flush or sticky ends with either 3' or 5' overhangs. In some situations, the presence of sticky ends may be desired as a specific site for linking. For the most part only one restriction enzyme will be used, although in some situations two or more enzymes may be used.

In some instances, the sample may involve the reverse transcription product of messenger RNA, where the mixture may be relatively small sequences of DNA and RNA. If desired, the RNA may be hydrolyzed, leaving only the DNA sequences. In this manner, one would have a composition of solely single-stranded DNA. The single-stranded DNA could then be converted into dsDNA using an enzyme such as DNA polymerase.

Once the sample has been digested or treated in the appropriate manner to provide the desired terminus, the dsDNA may be labeled. The choice of sequence other than the terminus and immediately adjacent nucleotide(s) will generally be arbitrary. The labeling moiety other than the portion of the restriction endonuclease recognition site, e.g. the complementary blunt end, cohesive end or overhang, will usually have at least three base pairs (bp) and may have 50 or more, usually up to about 200bp or more. The termini of the labeling moiety may lack phosphate, so that the labeling moiety cannot oligomerize, being ligatable solely to the phosphorylated sample.

For the labeling, various compositions may be employed having complementary ends, e.g. short double-stranded sequences, particularly molecules having ends produced by restriction enzymes, either cohesive ends or blunt ends, so as to link to a double-strand and label either one or both strands. The double-stranded sequence could be created from the hybridization of a single pair of oligonucleotides, from the snap-back or hairpin structure of a single oligonucleotide sequence with complementary internal sequences, or even from the hybridization of three or more oligonucleotides which hybridize to each other in a linear fashion so as to lie next to and across from each other so as to create such a double-stranded sequence. The double-stranded sequences could also be restriction fragments themselves or derivatized restriction fragments possessing termini satisfying the required conditions of sequence and being cohesive to the termini being labeled. By carrying out the ligation of the labeling moiety in the presence of the restriction enzyme, excesses of the labeling moiety may be avoided.

The labeling composition will have usually from one to three oligonucleotide strands. For the most part there will only be two strands, as has been described above. However, three strands provide some flexibility and may find particular application where the restriction enzyme digestion results in a 3' overhang. With three strands, one may employ a bridging strand, and two additional strands, each hybridizing with adjacent portions of the bridging strand, one strand proximal to the 3' end of the bridging strand (the labeling strand) and the other proximal to the 5' end of the bridging strand (the adapter strand). The labeling strand will provide a label or a sequence of interest, e.g. a promoter; the adapter strand will normally abut the strand of the fragment having the same 5'-3' direction and at the other end, the-labeling strand.

The adapter strand will have its 5' end phosphorylated and will contain the particular sequence necessary to destroy the recognition site of the restriction enzyme of interest. Upon introduction of the ligase, the labeling strand becomes ligated to the adapter strand and the adapter to the fragment.


By using three strands, one can have a substantially universal sequence where only one strand need be changed for each restriction site. In this way the labeled strand may be kept constant, while only the adapter strand involved in providing the complementary terminus need be changed. The adapter strand which hybridizes to the bridging strand can provide for a cohesive terminus, where the adapter strand is the overhang or where the bridging strand is the overhang, or a flush end to provide for ligation to the fragment.

In a particular example shown below, two oligonucleotides are synthesized, at least one of which contains the label, here a dye, to be added to the nucleic acid samples. The restriction enzyme HindIII has been used in this example to produce fragments with a 5' protruding sticky end.

5

## Ligation Point

10



15

The oligonucleotides are synthesized so as to be complementary to each other and, when hybridized to each other, to have a protruding end complementary to a sticky end of the sample nucleic acid fragment to be labeled. Alternatively, the synthesized oligonucleotides may have a flush end when hybridized to enable ligation to a flush ended fragment. Thus, when a ligating enzyme is added, the labeled oligonucleotide becomes covalently attached to the sample nucleic acid fragment.

The sequence of the oligonucleotides shown in the example above was chosen so that after correct ligation occurs the recognition sequence of the enzyme is destroyed. This choice provides a unique advantage in using ligation labeling: if the cognizant restriction enzyme is present and operational during ligation, then any ligation of sample nucleic acid to itself will be re-cut. This property yields two significant advantages: first, restriction activity and ligation labeling can occur simultaneously in the same vessel thus minimizing handling and manipulations; second, a large molar excess of the labeling moiety is no longer needed to prevent sample nucleic acid from being ligated to itself. The labeling example shown can be generalized to any restriction enzyme where synthetic oligonucleotides can be ligated into a cleaved restriction enzyme site, where the oligonucleotide contains a sequence that destroys the recognition site of the enzyme. Such a sequence may involve a base change, e.g. from cytosine to thymidine, or perhaps substitution of a derivatized base such as 5-methyl-cytosine or 3-methyl adenosine, or by substitution of an analog like inosine.

In all examples above and below where restriction enzymes are used for cutting nucleic acid strands at defined recognition sequences, the use of sequence specific DNA cleaving molecules such as natural product analogs, metal ion complexes, peptide fragments, etc. is also possible, e.g. Moser and Dervan, *Science* (1987) 238:645-650.

The labeling need not be direct but may be indirect. That is, the nucleic acid sequence may be modified with a molecule which may then bind to a second molecule which will provide for a detectable signal or other desired property. For example, the nucleic acid sequence may be modified with biotin, where subsequently the nucleic acid sequence may be combined with avidin or streptavidin to which various detectable labels may be conjugated. Alternatively, various ligands may be used other than biotin in conjunction with their naturally occurring receptors or immunoglobulins specific for the ligand.

A wide variety of detectable labels may be used, particularly those which allow for convenient detection. The detection may be as a result of electromagnetic radiation, such as radioactivity, light absorption in the ultraviolet or visible range, fluorescence, or chemiluminescence, enzymes which produce a detectable product or destroy a detectable substrate, stable free radicals, or the like. The various molecules providing for these properties may be joined to the sequence in accordance with conventional ways, either directly or indirectly, depending upon the particular manner of labeling.

As detectable labels, various radioactive elements may be employed, such as  $^{32}\text{P}$ ,  $^{125}\text{I}$ ,  $^{14}\text{C}$ ,  $^3\text{H}$ ,  $^{35}\text{S}$ ; fluorescers, such as fluorescein, rhodamine, phycobiliprotein, rare earth chelates, derivatives thereof, etc., where the fluorescers may be individual molecules or joined in tandem to a nucleic acid or non-(nucleic acid) backbone; enzymes such as horseradish peroxidase, by itself or in conjunction with glucose oxidase, xanthine oxidase, alkaline phosphatase, glucose-6-phosphate dehydrogenase, or the like, usually employing enzymes which react with a substrate to provide a fluorescent or light absorbing product; a member of a specific binding moiety-receptor pair, such as biotin-avidin or streptavidin, or complementary nucleic acid sequences; as well as any other label which provides for detection and can be used in the subject invention.

The following examples are offered by way of illustration and not by way of limitation.


## EXPERIMENTAL

## Example 1

- 5 Use of ligation to label a probe with the ligand biotin.
1. Oligodeoxynucleotides with structures I and II are synthesized on an Applied Biosystem Model 381A DNA synthesizer according to the manufacturer's directions. Structure I is synthesized with C (cytosine) in the X positions shown. The C's are then converted to the structure of X shown by a transamination reaction performed as described by Draper, *Nucleic Acids Research* (1984) 12:988 ff, followed by  
 10 reaction with long chain arm biotin according to the manufacturer's directions (Pierce Chemical Co., Rockford, IL).
  2. A reaction mixture is prepared by combining the following reagents:
    - 1  $\mu$ l of 1 pmole/ $\mu$ l of pSP64 plasmid (Promega, Madison, WI) in 10 mM Tris HCl, 1 mM EDTA, pH 8.0 (TE)
    - 15 - 1  $\mu$ l of 10x Medium Salt Buffer (Maniatis *et al.*, *supra*)
    - 1  $\mu$ l of 10mM ATP
    - 1  $\mu$ l of 1 unit/ $\mu$ l T4 ligase (Boehringer Mannheim, Indianapolis, IN)
    - 1  $\mu$ l of biotinylated oligodeoxynucleotide (Structure I containing 2.5 pmole in TE)
    - 1  $\mu$ l of complementary oligodeoxynucleotide (Structure II containing 2.5 pmoles in TE)
    - 20 - 3  $\mu$ l water
    - 1  $\mu$ l of 10 units/ $\mu$ l HindIII restriction enzyme (Boehringer Mannheim, Indianapolis, IN)
  3. The mixture is incubated for 1 hour at 37 °C.
  4. The reaction is stopped by adding 1  $\mu$ l of 0.2M EDTA.

## 25 Structure I

5' > TXXXTTTTTTTTTTTTAGTTATGATGTTGT <3' Where X =



## 45 Structure II

5'-AGCTACAACATCATAACT

## Example 2

- 50 Use of ligation to label sample nucleic acid with fluorescent dyes.
1. Using an Applied Biosystem Model 381 DNA synthesizer, an 18 nucleotide oligomer is synthesized and purified following the manufacturer's directions. The 5' end is terminated with an amino group using Amino-Link™ (Applied Biosystems). This amino group is coupled to fluorescein N-hydroxy succinimide, again according to the manufacturer's directions (Applied Biosystems).
  2. Using an Applied Biosystems Model 381 DNA synthesizer, a 20 nucleotide oligomer is synthesized and purified following the manufacturer's directions. The synthesized sequence is  
 55 5' AGC TAC AAC GTC GTG ACT GG 3'

The sequence is chosen so that the first 14 nucleotides (from the 5' end) are complementary to the 3' end of the fluorescein labeled 18-mer and the four nucleotides at the 3' end of the 18 mer are complementary to the 5' sticky end overhang generated by the restriction enzyme HindIII. The particular sequence chosen will destroy the recognition sequence of HindIII when the 18-mer/20-mer duplex is formed and then is ligated to the sticky ends of target DNA that has been cut with the HindIII restriction enzyme.

3. A reaction mixture is prepared by mixing the following reagents:

- 1 µg of lambda phage target DNA in 1 µl of TE
- 0.9 µl of 10x HindIII reaction buffer (BRL Gaithersburg, MD)
- 3.0 µl of the 18-mer in TE; the number of moles should be twice that of the expected number of sticky ends generated when the HindIII digests the 1 µg of target DNA.
- 2.0 µl of the 20-mer in TE; the number of moles should be equal to that of the 18-mer.
- 1.0 µl of 10 mM dithiothreitol
- 1.0 µl of 3 mM ribose ATP
- 0.5 µl of HindIII enzyme (12 units/µl)
- 0.5 µl of ligase enzyme (0.5 units)

4. Incubate at 37 °C for 1 hour.

5. Add 0.5 µl of 0.2M EDTA and 1.0 µl of 20µg/µl glycogen in water.

6. Clean up mixture by performing two phenol/chloroform extractions. Add 10 µl each of phenol and chloroform. Mix and centrifuge. Remove and discard lower phase. Repeat. (Maniatis et al., supra).

7. Add ≥1 µl 3M NaAc pH 5.5 and 25 µl of 95% ethanol. Mix. Let stand for 30 minutes. Centrifuge.

8. Wash the precipitate with 500 µl of 70% ethanol.

9. Use a vacuum centrifuge to dry sample.

10. Resuspend in 50 µl of 10 mM Tris, 1 mM EDTA, pH 8.0.

11. An aliquot of the reaction mixture is applied to a 0.6% agarose gel run at 3 volts/cm in 1x TBE (Tris-borate EDTA) buffer for 4 hours. The fluorescent bands migrating through the gel are detected by an Applied Biosystem 370A DNA sequencer adapted to read horizontal agarose gels. Fluorescent peaks are detected corresponding to the 560, 2027, 2322, 4361, 6557, 9416, and 23,130 base pair fragments in the HindIII cut lambda DNA.

It is evident from the above results that a simple effective process for labeling or modifying termini of double-stranded DNA is provided. Smaller amounts of the labeling moiety are required, while oligomerization of the sample is substantially prevented. Labeling can occur in the same reaction vessel in which restriction or specific fragmentation is accomplished. Thus, a homogeneous product is obtained which provides for accurate sizing, detection and ease of further manipulation.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains.

## Claims

1. A method for extending dsDNA fragments with a moiety of interest comprising :  
combining in a reaction mixture said fragments in the simultaneous presence of ligase and a restriction enzyme, with dsDNA comprising said moiety and having a terminus complementary to a terminus of said fragments, wherein said fragments have predetermined termini as a result of digestion with said restriction enzyme, said fragments have terminal phosphates and said complementary termini of said dsDNA lack a terminal phosphate and ligation of said dsDNA results in a sequence different from the sequence cleaved by said restriction enzyme,  
whereby said fragments and dsDNA are covalently joined.
2. A method according to Claim 1 , wherein said moiety comprises a ligand.
3. A method according to Claim 2, wherein said ligand is a label capable of providing a detectable signal.
4. A method according to Claim 1, wherein said moiety is a DNA sequence of interest.
5. A method according to Claim 4, including the additional steps of:  
selecting a fraction of said covalently joined fragments and dsDNA;  
adding to said selected fraction a DNA polymerase, nucleotide triphosphates and sequences complementary to the strands of said dsDNA; and



carrying out a polymerase chain reaction to expand said selected fraction.

6. A method according to Claim 5, wherein said selecting is size selection by electrophoresis.
- 5 7. A method according to Claim 1, wherein said DNA fragments are obtained by adding precursor DNA to be fragmented to said reaction mixture, whereby said precursor DNA is cleaved by said restriction enzyme.
8. A method for labeling DNA fragments with a ligand comprising:  
10 combining said fragments in the simultaneous presence of ligase and a restriction enzyme, with ligand labeled dsDNA of fewer than about 200bp and having a terminus complementary to a terminus of said fragments, wherein said fragments have predetermined termini as a result of digestion with said restriction enzyme, said fragments have terminal phosphates and said complementary termini of said dsDNA lack a terminal phosphate and ligation of said dsDNA results in a sequence different from the  
15 sequence cleaved by said restriction enzyme,  
whereby said fragments and dsDNA are covalently joined to label said fragments.
9. A method according to Claim 8, wherein said ligand is biotin.
- 20 10. A method according to Claim 8, wherein said ligand is a radionuclide, fluorescer or an enzyme.
11. A method according to Claim 8, wherein said termini have cohesive ends.
12. A method according to Claim 8, wherein said fragments are obtained by the step of: digesting genomic  
25 DNA with at least one restriction enzyme to provide fragments of less than about 200kbp.
13. A labeling composition for binding to a restricted dsDNA fragment resulting in loss of the restriction recognition site by simultaneous restriction and ligation, said composition comprising  
a bridging strand and first and second strands hybridized to said bridging strand, wherein said  
30 strands hybridize contiguously to said bridging strand ; said first strand is a labeling strand providing for a double-stranded DNA sequence of interest and a fluorescent label ; said second strand is an adapter strand hybridizing to said bridging strand to provide a cohesive end or blunt end with said bridging strand, and wherein said adapter strand contains a particular sequence necessary to destroy the recognition site of a restriction enzyme of interest.

35

#### Patentansprüche

1. Verfahren zur Verlängerung von dsDNA-Fragmenten mit einem interessierenden Rest, umfassend:  
die Kombination dieser Fragmente in einem Reaktionsgemisch, bei gleichzeitiger Anwesenheit von  
40 Ligase und einem Restriktionsenzym, mit dsDNA, die diesen Rest enthält und ein Ende aufweist, das komplementär zu einem Ende dieser Fragmente ist, wobei diese Fragmente vorbestimmte Enden als Ergebnis der Digestion mit dem Restriktionsenzym haben, diese Fragmente terminale Phosphate aufweisen und die komplementären Enden der dsDNA kein terminales Phosphat aufweisen und die Ligation dieser dsDNA zu einer Sequenz führt, die verschieden von der durch das Restriktionsenzym  
45 gespaltenen Sequenz ist,  
wodurch diese Fragmente und dsDNA kovalent miteinander verbunden werden.
2. Verfahren nach Anspruch 1, bei dem der Rest einen Liganden umfaßt.
- 50 3. Verfahren nach Anspruch 2, bei dem der Ligand eine Markierung ist, die geeignet ist, ein feststellbares Signal zu liefern.
4. Verfahren nach Anspruch 1, bei dem der Rest eine interessierende DNA-Sequenz ist.
- 55 5. Verfahren nach Anspruch 4, das folgende zusätzliche Stufen umfaßt: die Wahl einer Fraktion der kovalent verbundenen Fragmente und dsDNA; den Zusatz zu dieser gewählten Fraktion von einer DNA-Polymerase, Nukleotid-triphosphaten und Sequenzen, die komplementär zu den Strängen der dsDNA sind; und

die Durchführung einer Polymerase-Kettenreaktion, um die gewählte Fraktion zu verlängern.

6. Verfahren nach Anspruch 5, bei dem die Wahl eine Größenwahl durch Elektrophorese ist.
- 5 7. Verfahren nach Anspruch 1, bei dem die DNA-Fragmente erhalten werden durch Zusatz von Vorläufer-DNA, die fragmentiert werden soll, zu dem Reaktionsgemisch, wodurch die Vorläufer-DNA durch das Restriktionsenzym gespalten wird.
8. Verfahren zur Markierung von DNA-Fragmenten mit einem Liganden, umfassend:  
10 die Kombination der Fragmente bei gleichzeitiger Anwesenheit von Ligase und einem Restriktionsenzym, mit mit Liganden markierter dsDNA mit weniger als etwa 200bp und mit einem Ende, das komplementär zu einem Ende der Fragmente ist, wobei die Fragmente vorbestimmte Enden als Ergebnis der Digestion mit dem Restriktionsenzym haben, wobei die Fragmente terminale Phosphate aufweisen und die komplementären Enden der dsDNA kein terminales Phosphat aufweisen und die  
15 Ligation der dsDNA zu einer Sequenz führt, die verschieden von der durch das Restriktionsenzym gespaltenen Frequenz ist, wodurch die Fragmente und dsDNA kovalent miteinander verbunden werden, um die Fragmente zu markieren.
- 20 9. Verfahren nach Anspruch 8, bei dem der Ligand Biotin ist.
10. Verfahren nach Anspruch 8, bei dem der Ligand ein Radionuklid, ein Fluoreszenz verleihendes Material oder ein Enzym ist.
- 25 11. Verfahren nach Anspruch 8, bei dem die Terminationsorte kohäsive Enden haben.
12. Verfahren nach Anspruch 8, bei dem die Fragmente erhalten werden durch die Stufe des: Digestierens von genomischer DNA mit mindestens einem Restriktionsenzym zur Erzielung von Fragmenten mit weniger als etwa 200kbp.
- 30 13. Markierungszusammensetzung zur Bindung an ein restriktiertes dsDNA-Fragment, die zu einem Verlust des Erkennungsortes für die Restriktion durch gleichzeitige Restriktion und Ligation führt, wobei die Zusammensetzung umfaßt:  
einen Brückenstrang und erste und zweite Stränge, die mit dem Brückenstrang hybridisiert sind, wobei  
35 diese Stränge aufeinanderfolgend mit dem Brückenstrang hybridisieren; wobei der erste Strang ein Markierungsstrang ist, der eine interessierende doppelsträngige DNA-Sequenz und eine fluoreszierende Markierung bereitstellt; der zweite Strang ein Adaptorstrang ist, der mit dem Brückenstrang hybridisiert unter Bereitstellung eines kohäsiven Endes oder stumpfen Endes mit dem Brückenstrang und wobei der Adaptorstrang eine spezielle Sequenz enthält, die zur Zerstörung des Erkennungsortes eines  
40 interessierenden Restriktionsenzym benötigt wird.

## Revendications

1. Procédé d'extension de fragments d'ADN bicaténaire (ADNbc) comportant un segment d'intérêt,  
45 comprenant :  
la réunion dans un mélange réactionnel desdits fragments en présence simultanée de ligase et d'une enzyme de restriction, avec de l'ADNbc comprenant ledit segment et ayant une extrémité complémentaire à une extrémité desdits fragments, lesdits fragments ayant des extrémités préétablies résultant de la digestion par ladite enzyme de restriction, lesdits fragments ayant des phosphates  
50 terminaux et lesdites extrémités complémentaires dudit ADNbc étant dépourvues de phosphate terminal et la ligature dudit ADNbc donnant une séquence différente de la séquence coupée par ladite enzyme de restriction,  
ce par quoi lesdits fragments et ADNbc sont liés par covalence.
- 55 2. Procédé selon la revendication 1, dans lequel ledit segment comprend un ligand.
3. Procédé selon la revendication 2, dans lequel ledit ligand est un marqueur capable de fournir un signal détectable.

4. Procédé selon la revendication 2, dans lequel ledit segment est une séquence d'ADN d'intérêt.
5. Procédé selon la revendication 4, comprenant les étapes supplémentaires suivantes:  
sélection d'une fraction desdits fragments et ADNbc liés par covalence;  
5 addition à ladite fraction sélectionnée d'une ADN polymérase, de nucléotide-triphosphates et de séquences complémentaires des brins dudit ADNbc; et  
mise en oeuvre d'une réaction de polymérisation en chaîne pour étendre ladite fraction sélectionnée.
- 10 6. Procédé selon la revendication 5, dans lequel ladite sélection est une sélection en fonction de la taille par électrophorèse.
7. Procédé selon la revendication 1, dans lequel lesdits fragments d'ADN sont obtenus par addition au mélange réactionnel d'ADN précurseur destiné à être fragmenté, ce par quoi ledit ADN précurseur est  
15 coupé par ladite enzyme de restriction.
8. Procédé pour le marquage de fragments d'ADN par un ligand, comprenant:  
la réunion desdits fragments en présence simultanée de ligase et d'une enzyme de restriction,  
avec de l'ADNbc marqué par un ligand, de moins d'environ 200 pb et ayant une extrémité complémen-  
20 taire d'une extrémité desdits fragments, lesdits fragments ayant des extrémités préétablies résultant de la digestion par ladite enzyme de restriction, lesdits fragments ayant des phosphates terminaux et lesdites extrémités complémentaires dudit ADNbc étant dépourvues de phosphate terminal et la  
ligature dudit ADNbc donnant une séquence différente de la séquence coupée par ladite enzyme de  
restriction,  
25 ce par quoi ledits fragments et ADNbc sont liés par covalence pour le marquage desdits fragments.
9. Procédé selon la revendication 8, dans lequel ledit ligand est la biotine.
10. Procédé selon la revendication 8, dans lequel ledit ligand est un radionucléide, une substance  
30 fluorescente ou une enzyme.
11. Procédé selon la revendication 8, dans lequel lesdites extrémités sont cohésives.
12. Procédé selon la revendication 8, dans lequel lesdits fragments sont obtenus par l'étape suivante:  
35 digestion d'ADN génomique par au moins une enzyme de restriction, pour donner des fragments de moins de 200 kpb.
13. Composition de marquage pour la liaison à un fragment d'ADNbc digéré par restriction, ayant pour  
résultat la perte du site de reconnaissance par une enzyme de restriction, par restriction et ligature  
40 simultanées, ladite composition comprenant:  
un brin pontant et un premier brin et un second hybridés avec ledit brin pontant, lesdits brins  
s'hybridant de façon contiguë avec ledit brin pontant; ledit premier brin étant un brin marqueur  
fournissant une séquence intéressante d'ADN bicaténaire et un marqueur fluorescent, ledit second brin  
étant un brin de raccord s'hybridant avec ledit brin pontant pour produire une extrémité cohésive ou  
45 une extrémité franche avec ledit brin pontant, et ledit brin de raccord contenant une séquence  
particulière nécessaire pour détruire le site de reconnaissance d'une enzyme de restriction intéres-  
sante.

50

55